Living Homeopathy International, which sells homeopathic products in Hong Kong, raised the proposed deal size for its upcoming IPO on Friday.
The Hong Kong, China-based company now plans to raise $19 million by offering 3.8 million shares at a price range of $4 to $6. The company had previously filed to offer 1.3 million shares at the same price range. At the midpoint of the revised deal size, Living Homeopathy International will raise 200% more in proceeds than previously anticipated.
Living Homeopath International offers healthcare products, including homeopathic remedies (9% of FY24 revenue), homeopathic co-remedies (80%), and flower remedies (4%), which it primarily acquires from manufacturers and resells under its LIVING brand; as well as personal care (2%; e.g. mouthwash, toothpaste, shampoo) and water filter products (4%), which it develops and works with manufacturers to produce. According to Frost & Sullivan, the company had a leading 41% market share of homeopathic product in Hong Kong in 2023.
Living Homeopathy International was founded in 1994 and booked $9 million in revenue for the 12 months ended September 30, 2025. It plans to list on the Nasdaq under the symbol LHI. Revere Securities is the sole bookrunner on the deal.
